ESKATA™ is the first and only FDA-approved topical treatment for raised SKs. You didn’t choose to get raised SKs, but you can choose to treat them.
With its proprietary solution and soft-tip, pen-like applicator, healthcare providers can target and treat raised SKs with ESKATA.
Seborrheic Keratoses causes and symptoms
SKs are non-contagious and non-cancerous skin growths that can occur anywhere on the body. They first appear as small rough bumps, but often thicken and grow into a wart-like lump.
SKs are estimated to affect approximately 83 million adults in the US and is more widespread than skin diseases such as acne, psoriasis, and rosacea.
Treatments for SKs are often painful or invasive and can lead to scarring or pigmentation.
Eskata’s mechanism of action
Eskata contains a high-concentration hydrogen peroxide formulation as a 40% weight / weight (w/w) topical solution. It can be applied directly to the affected area using a pen-like applicator.
The mechanism of action (MoA) is designed to penetrate the SK lesions and cause oxidative damage so that the cells can be shed.
Is ESKATA right for you?
If the raised spots on your face or neck are concerning you, the first step is going to your healthcare provider to see if they are SKs.
A skin condition like raised SKs doesn’t have to be “serious” to make you seek treatment. Healthcare providers can help with many non-medical skin issues that have a big impact on the way you view yourself.
What to expect during treatment?
In clinical studies, 18% of patients experienced clearance of 3 out of 4 of their raised SKs treated with ESKATA vs 0% with vehicle. Results were evaluated at Day 106 after initial treatment. Nearly all patients received 2 treatments. The most common side effects of ESKATA include: itching, stinging, crusting, swelling, redness, and scaling.
How does ESKATA work?
ESKATA™ (hydrogen peroxide) topical solution, 40% (w/w) is indicated for the treatment of seborrheic keratoses that are raised. Two identical, multicenter, randomized, double-blind, vehicle-controlled US trials. Subjects with 4 clinically typical SKs that are raised were randomized to treatment with either ESKATA or vehicle.
Each subject had at least 1 SK on the face and 1 on the trunk or extremities. Subjects ranged from 42 to 91 years of age, 58% were female, and 98% were Caucasian. Nearly all patients received 2 treatments
How long does it take to see results with ESKATA?
Your healthcare provider will evaluate your results approximately 3 weeks after treatment with ESKATA. If your treated raised SKs are not clear, your healthcare provider may apply ESKATA once more, as long as the treatment area is not irritated. In clinical studies, results were evaluated at Day 106 after initial treatment.
What are the most common side effects?
ESKATA is likely to cause a stinging sensation at the time of application. The most common side effects include itching, stinging, crusting, swelling, redness, and scaling.
Can I apply ESKATA myself?
No, only a doctor, nurse, or other trained healthcare provider can apply ESKATA.
How do I find a doctor to treat my raised SKs?
You can use our Doctor Finder to locate a doctor near you.
Will my raised SK come back after being treated with ESKATA?
Clinical studies evaluated final treatment results at Day 106, but not the recurrence of raised SKs. Please consult with your healthcare provider.
|Treatment Type||Fractional Laser Skin Resurfacing, Skin Resurfacing Treatments|
|Treatment Problem or Condition||Moles, Warts|
|Skin Type||Aging Skin|
Do not apply ESKATA to the eyes or mucous membranes. Avoid treating seborrheic keratoses within the orbital rim. Direct contact with the eye can cause corneal injury (erosion, ulceration, perforation, and scarring), chemical conjunctivitis, eyelid edema, severe eye pain or permanent eye injury, including blindness. If accidental exposure occurs, flush with water for 15 to 30 minutes, initiate monitoring and further evaluation as appropriate.
Skin reactions occurred in the treatment area after application of ESKATA. Severe local skin reactions included erosion, ulceration, vesiculation and scarring. Do not retreat until the skin has recovered from any reaction caused by the previous treatment.
MOST COMMON ADVERSE REACTIONS
The most common adverse reactions include erythema (99%), stinging (97%), edema (91%), scaling (90%), crusting (81%), and pruritus (58%).
DOSAGE AND ADMINISTRATION
ESKATA is to be administered by a healthcare provider. For topical use only. Not for oral, ophthalmic, or intravaginal use. Not for open or infected seborrheic keratoses.